^
Association details:
Biomarker:TMB-H
Cancer:Neuroendocrine Tumor
Drug:Keytruda (pembrolizumab) (PD1 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
Published date:
04/14/2021
Excerpt:
Poorly differentiated neuroendocrine carcinoma/large or small cell: Pembrolizumab can be considered for patients with mismatch repair-deficient (dMMR), microsatellite instability-high (MSI-H), or advanced tumor mutational burden-high (TMB-H) tumor(MSI-H). or afvanced tumor mutational burden-high (TMB-H) tumors...
Evidence Level:
Sensitive: C1 - Off-label
  (Approved for Solid Tumor)
New
Excerpt:
KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated:...for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

Excerpt:
...- Any advanced solid tumor that has failed at least one line of therapy and is TMB-H (≥10 mut/Mb, F1CDx assay), excluding dMMR/MSI-H tumors....
Trial ID: